Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study of KN026, a bispecific antibody (BsAb) co-developed with CSPC Pharmaceutical Group (HKG: 1093), in combination with docetaxel (albumin-bound) and chemotherapy as adjuvant therapy for HER2-positive (HER2+) breast cancer (BC). The 1,800-patient randomized trial compares KN026-based regimen vs. trastuzumab + pertuzumab standard of care, targeting invasive disease-free survival (iDFS) as primary endpoint.
Global next-generation HER2-targeted therapy – enhanced efficacy via dual blockade + immune effector function
Development Partner
CSPC Pharmaceutical Group (HKEX: 1093) – China rights for BC and gastric cancer (August 2021 agreement)
Partnership History
Date
Agreement
August 2021
Alphamab enters collaboration and licensing agreement with CSPC Pharma
Scope
Development and commercialization of KN026 in mainland China for breast cancer and gastric cancer
Financial Terms
Not disclosed; typical milestone/royalty structure for Phase II/III assets
Strategic Context & Competitive Landscape
Factor
Implication
HER2+ Breast Cancer Market
~20% of all breast cancers; adjuvant therapy standard (trastuzumab + pertuzumab + chemotherapy) reduces recurrence but 15–20% still relapse – unmet need for superior regimens
Bispecific HER2 Rationale
Dual epitope blockade (II + IV) provides enhanced receptor clustering inhibition vs. trastuzumab (Epitope IV only) or pertuzumab (Epitope II only); wild-type Fc adds immune-mediated tumor killing
KN026 Differentiation
Only dual-epitope HER2 BsAb with wild-type Fc in Phase III; competitors (Zymeworks’ zanidatamab, Sutro’s STRO-002) have modified Fc or different epitope combinations
Adjuvant Setting Strategy
High-risk population (≥4 positive nodes) where recurrence risk justifies intensified therapy; success here supports broader adjuvant label
Global Ambition
Phase III design enables ex-China regulatory filings (FDA, EMA); Alphamab retains worldwide rights ex-China via CSPC China partnership structure
Clinical Timeline: Enrollment 2026–2028; interim iDFS analysis 2029; potential China NDA 2030 and global submissions 2031
Commercial Potential: Peak China sales RMB 2–3 billion annually assuming 20–30% share of high-risk HER2+ adjuvant market; global peak $1+ billion if approved in U.S./EU
Forward‑Looking Statements This brief contains forward‑looking statements regarding patient enrollment, iDFS outcomes, and regulatory pathways for KN026 in HER2+ breast cancer. Actual results may differ due to competitive dynamics with trastuzumab/pertuzumab biosimilars, safety profile in adjuvant setting, and reimbursement negotiations for novel HER2-targeted therapies.-Fineline Info & Tech
By Fineline Cube